UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: December 30, 2023 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF ☐ 1934 Commission File Number: 001-14041 HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 04-2882273 (State or other jurisdiction of incorporation or organizat ...

Haemonetics Corporation (NYSE:HAE) Q2 2024 Earnings Conference Call November 2, 2023 8:00 AM ET Company Participants Olga Guyette – Senior Director, Investor Relations and Treasury Chris Simon – Chief Executive Officer Stewart Strong – President of our Global Hospital business James D'Arecca – Chief Financial Officer Conference Call Participants Anthony Petrone – Mizuho Group Lee Jagoda – CJS Securities Andrew Cooper – Raymond James Mike Matson – Needham & Company Michael Petusky – Barrington Research Opera ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 30, 2023 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF ☐ 1934 Commission File Number: 001-14041 HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 04-2882273 (State or other jurisdiction of incorporation or organiza ...

Financial Data and Key Metrics Changes - The company reported first quarter organic revenue growth of 21% and adjusted earnings per diluted share of $1.05, representing an 81% increase over the prior year [12][21] - Adjusted operating income was $70.2 million, an increase of $25 million or 56%, with an adjusted operating margin of 22.6%, up 540 basis points compared to the same period in fiscal 2023 [37][19] - Adjusted gross margin was 54.2%, 100 basis points lower than the same period last year, benefiting from price, volume, and favorable geographic and product mix [36] Business Line Data and Key Metrics Changes - Plasma revenue grew 35% in the first quarter, with North America disposables growing 41% due to strong U.S. collections and pricing [9] - Hospital revenue increased by 14%, driven by improved procedure volume and staffing levels at U.S. hospitals [13] - Hemostasis Management grew 14%, with North America growing 23% due to increased utilization of TEG and strong capital sales [14] - Transfusion Management saw strong performance driven by market share gains in North America and Europe, although offset by unfavorable order timing outside the U.S. [15] - Vascular Closure revenue grew 27%, with higher utilization rates in U.S. hospitals [32] Market Data and Key Metrics Changes - The company is increasing its full-year Plasma organic revenue growth guidance from 3%-6% to 8%-11% [12] - The company anticipates an organic revenue decline of 2% to 6% in the Blood Center business due to a voluntary product recall and timing of commercial opportunities [35] Company Strategy and Development Direction - The company is focused on operational excellence to improve productivity and risk management, enabling margin expansion and investment in growth opportunities [8] - The launch of Vascular Closure products in Europe and Japan is expected to establish new foundations for growth [16] - The company plans to utilize its capital capacity for M&A, organic growth investments, and opportunistic share buybacks [23] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ability to capitalize on positive macroeconomic trends supporting rising collection volumes [12] - The company acknowledged a challenging macro environment and anticipated impacts from changes in geographic and product mix [38] - Management remains cautious in forecasting due to uncertainties such as blood center order timing and the impact of sanctions [61][62] Other Important Information - The company welcomed Diane Bryant to its Board of Directors, bringing over 30 years of leadership experience in technology and healthcare [29] - The NexSys Plasma collection system is expected to enhance efficiency and reduce costs, with FDA clearance for new technology [30][31] Q&A Session Summary Question: What is the upgrade path for Express Plus technology? - The upgrade involves both software and some capital components, with a focus on ensuring no disruption to plasma center operations [57] Question: How is the company addressing inventory replenishment among fractionators? - The company believes it is still in the early stages of recovery, with significant room to reach pre-pandemic inventory levels [46] Question: What factors contributed to the gross margin improvement? - Price and favorable mix helped improve gross margins, although there were lingering inefficiencies from previous volume increases [47] Question: What is the outlook for international growth? - The company expects international growth to continue, albeit potentially at lower gross margins [51] Question: How is the company managing SG&A expenses? - SG&A as a percentage of revenue decreased significantly, attributed to disciplined investments and timing of annual bonuses [71][89] Question: What is the status of the Cardiva launches outside the U.S.? - The company is making progress in Europe and Japan, with positive early feedback from clinicians [75][90]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Exact name of registrant as specified in its charter) Massachusetts 04-2882273 (State or other jurisdiction of incorporation or organization) 125 Summer Street For the quarterly period ended: July 1, 2023 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF ☐ 1934 Commission File Number: 001-14041 HAEMON ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended April 1, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-14041 HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 04-2882273 (State or other jurisdiction of incorpora ...

Haemonetics Corporation (NYSE:HAE) Q4 2023 Earnings Conference Call May 11, 2023 8:00 AM ET Company Participants David Trenk - Manager, Investor Relations Christopher Simon - Chief Executive Officer James D'Arecca - Executive Vice President and Chief Financial Officer Conference Call Participants Anthony Petrone - Mizuho Larry Solow - CJS Securities David Turkaly - JMP Securities Mike Matson - Needham & Company Drew Ranieri - Morgan Stanley Michael Petusky - Barrington Research Operator Good day and thank y ...

Haemonetics Corporation (NYSE:HAE) Q3 2023 Earnings Conference Call February 7, 2023 8:00 AM ET Company Participants David Trenk - Manager, Investor Relations Chris Simon - Chief Executive Officer Roy Galvin – President, Global Plasma and Blood Center James D'Arecca - Chief Financial Officer Conference Call Participants Drew Ranieri - Morgan Stanley Mike Matson - Needham & Company Joanne Wuensch - Citi Anthony Petrone - Mizuho Andrew Cooper - Raymond James Dave Turkaly - JMP Operator Good day, and welcome t ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: December 31, 2022 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF ☐ 1934 Commission File Number: 001-14041 HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 04-2882273 (State or other jurisdiction of incorporation or organizat ...

4 | --- | --- | --- | --- | |------------------------------------------------|---------------------------------------------------|---------------------------------|-------------------------------------------| | | | | | | Compete in winning segments and geographies | | Revenue Profitability Cash Flow | GROWTH | | Achieve leading positions | DIVERSIFICATION • Business Segments | | SUSTAINABILITY • Economic | | Deliver superior operating performance | • Customers • Geographies • Business Models | | • People • ...